The four older patients with X-linked Alport syndrome showed a more uniform, consistent response to SGLT2-inhibition: in the female patient 3, SGLT2i was able to compensate for the withdrawal of the ACEi (because of angioedema), and the CKD level remained unchanged at G1A3. This evidence concerns the gene SLC5A2 and Alport syndrome.